UC San Diego scientists identify genetic switch linking childhood dementia to Alzheimer's
This digest was compiled by AI from multiple sources — links to the originals are below.
Researchers at UC San Diego School of Medicine reported in Immunity that a protein switch called MITF/TFE drives brain-cell destruction in both Sanfilippo syndrome (MPS IIIA) and Alzheimer's disease. The study places the origin of damage inside cells, not in external amyloid plaques. The team says early enzyme or cell therapy before the switch turns harmful may stop brain damage.
The Genetic Switch
Researchers at UC San Diego School of Medicine found that the MITF/TFE protein family acts as a genetic switch inside microglia, the brain's immune cells. In healthy tissue, microglia use lysosomes to clear protein waste and harmful microbes; when sulfamidase is missing or ageing disrupts the process, waste accumulates. The switch initially activates to protect the brain, but overload causes it to trigger chronic inflammation and neuron death. The study, published in Immunity, links the lysosomal collapse in Sanfilippo syndrome (MPS IIIA) to the same mechanism in Alzheimer's disease, which affects millions of people.
Damage Origin Reversal
The finding challenges the long-held view that amyloid plaques outside brain cells drive Alzheimer's damage from outside inward. Lead author Dr. Christopher Balak reported that the cellular collapse in childhood-onset Sanfilippo syndrome is identical to that in ageing brains of Alzheimer's patients. The study places the origin of destruction in the failure of lysosomes inside the cell rather than external plaque accumulation. Both diseases share one cellular pathway, giving the team a clearer framework for studying a complex condition.
Early Treatment Strategy
Current drug development largely targets receptors on the cell surface; the new study points instead to the lysosomal mechanism and the MITF/TFE genetic switch inside the cell. The team argues that enzyme or cell therapy delivered before the switch turns harmful could halt brain damage entirely. Next-generation molecules would aim to keep microglia in a protective form and slow progression of Alzheimer's and other dementias. No clinical trial data were reported in the Immunity paper.
What's Next
Researchers aim to develop next-generation molecules that keep microglia in a protective state before the MITF/TFE switch turns harmful. It remains unclear whether early enzyme or cell therapy can fully halt Alzheimer's progression once clinical trials begin.
1 source
UC San Diego scientists identify genetic switch linking childhood dementia to Alzheimer's
